Waldenstr?m Macroglobulinemia, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 37-4


Book
June 2023
Region: North America
Elsevier Health Science
ID: 5755381

In this issue of Hematology/Oncology Clinics, guest editors Drs. Jorge J. Castillo, Prashant Kapoor, and Shayna Sarosiek bring their considerable expertise to the topic of Waldenstr�m Macroglobulinemia. Top experts in the field provide a focused update on the biology, diagnosis and management, and novel therapies for patients with Waldenstr�m macroglobulinemia, a rare blood cell cancer characterized by an excess of abnormal white blood cells in the bone marrow.

Contains 14 practice-oriented topics including clinical implications of genomic profile in Waldenstr�m macroglobulinemia; chemoimmunotherapy regimens in the frontline management of Waldenstr�m macroglobulinemia; management of relapsed or refractory Waldenstr�m macroglobulinemia; evaluation and management of aggressive transformation in Waldenstr�m macroglobulinemia; management of Waldenstr�m macroglobulinemia in limited-resource settings; and more.�
Provides in-depth clinical reviews of Waldenstr�m macroglobulinemia, offering actionable insights for clinical practice.�
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.�

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Clinical Implications of Genomic Profile in Waldenstr�m Macroglobulinemia Frontline Management of Waldenstr�m Macroglobulinemia with Chemoimmunotherapy Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenstr�m Macroglobulinemia BTK Inhibitors in the Frontline Management of Waldenstr�m Macroglobulinemia Future Directions in the Frontline Management of Waldenstr�m Macroglobulinemia The Management of Relapsed or Refractory Waldenstr�m's Macroglobulinemia Novel Agents in Waldenstr�m Macroglobulinemia Investigation and Management of Immunoglobulin M- and Waldenstr�m-Associated Peripheral Neuropathies Evaluation and Management of Bing-Neel Syndrome Evaluation and Management of Disease Transformation in Waldenstr�m Macroglobulinemia Management of Waldenstr�m Macroglobulinemia in Limited-Resource Settings

Authors

Jorge J Castillo Prashant Kapoor Mayo Clinic. Shayna Sarosiek Bing Center for Waldenstr�m Macroglobulinemia, Dana-Farber Cancer Institute.

Table of Contents

Authors

Related Topics

Related Products

Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

New Developments in Myeloma, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 38-2

Global Oncology: Disparities, Outcomes and Innovations Around the Globe, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 38-1

Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Oncology Collaboration and Licensing Deals 2019-2024